Heart failure - Pharmacologic Therapy and Historical Perspectives

Pharmacologic Therapy for Heart Failure Introduction Heart failure treatment has undergone a dramatic transformation over the past several decades. Once limited to diuretics and digitalis, modern pharmacotherapy now focuses on modifying the underlying neurohormonal dysfunction that perpetuates the disease. This shift represents a fundamental change in how we approach heart failure management: rather than simply relieving symptoms, we now use medications to slow disease progression and improve survival. Standard Quadruple Therapy for Heart Failure with Reduced Ejection Fraction The current standard of care for heart failure with reduced ejection fraction (HFrEF) consists of four medication classes used together: Angiotensin receptor–neprilysin inhibitor (ARNi) — primarily sacubitril/valsartan Beta-blocker Mineralocorticoid receptor antagonist (MRA) Sodium-glucose cotransporter 2 inhibitor (SGLT2i) These four drug classes work synergistically through different mechanisms to reduce mortality, improve symptoms, and reduce hospitalizations. The combination approach is more effective than any single agent alone. Renin–Angiotensin System Inhibitors The renin–angiotensin system (RAS) plays a central role in heart failure progression by increasing blood pressure and promoting heart remodeling. Blocking this system is therefore a cornerstone of therapy. Angiotensin receptor–neprilysin inhibitor (ARNi): According to American guidelines (2022), sacubitril/valsartan is the first-line RAS inhibitor for heart failure. This medication combines two mechanisms: it blocks angiotensin II receptors (like traditional ARBs) and simultaneously inhibits neprilysin, an enzyme that breaks down beneficial natriuretic peptides. This dual action makes it more powerful than traditional RAS inhibitors alone. Important drug interaction: If a patient is already taking an ACE inhibitor or ARB, you must wait at least 36 hours after stopping it before starting an ARNi. This washout period is necessary to prevent excessive vasodilation and hypotension. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs): These remain important alternatives. However, patients sometimes develop a chronic, dry cough with ACE inhibitors (occurring in roughly 10% of users). If this occurs, the patient can be switched to an ARB, which has a different mechanism and typically does not cause this cough. According to European guidelines, if symptoms persist despite standard therapy with an ACE inhibitor or ARB plus a beta-blocker and MRA, an ARNi should be added. Beta-Blockers Beta-blockers slow heart rate and reduce the force of heart contractions by blocking the effects of adrenaline on the heart. This may sound counterintuitive—why make the heart pump less forcefully?—but the benefit occurs because chronic adrenaline stimulation damages the heart over time. By reducing this stimulation, beta-blockers allow the heart to become more efficient and prevent further deterioration. Key benefits: When added to ACE inhibitor or ARB therapy, beta-blockers further improve symptoms and reduce mortality in HFrEF. Important limitation in atrial fibrillation: The mortality benefit of beta-blockers is smaller in patients who have both systolic dysfunction and atrial fibrillation. This is important because it may influence drug selection in these patients. Effect in HFpEF: In heart failure with preserved ejection fraction (HFpEF), beta-blockers modestly lower mortality but do not reduce hospital admissions for uncontrolled symptoms. This means they may help patients live longer but won't necessarily prevent worsening symptoms requiring hospitalization. Mineralocorticoid Receptor Antagonists Aldosterone is a hormone that causes the body to retain sodium and water, worsening heart failure. Mineralocorticoid receptor antagonists (MRAs)—primarily spironolactone or eplerenone—block aldosterone's effects. Clinical effects: Adding an MRA to beta-blocker and ACE inhibitor/ARB therapy improves symptoms and lowers mortality in HFrEF. This additive benefit demonstrates why quadruple therapy works better than any smaller combination. Sodium-Glucose Cotransporter 2 Inhibitors SGLT2 inhibitors are a newer drug class originally developed for type 2 diabetes. Their use in heart failure represents an important discovery: these drugs benefit heart failure patients regardless of whether they have diabetes. Key evidence: SGLT2 inhibitors lower both hospitalizations and mortality in HFrEF. The mechanism isn't fully understood but appears to involve improved cardiac efficiency and favorable effects on heart remodeling. Pharmacotherapy for Heart Failure with Preserved Ejection Fraction Heart failure with preserved ejection fraction (HFpEF) is managed quite differently from HFrEF because the underlying problem is different—the heart squeezes adequately, but it doesn't relax properly. This affects which medications are most beneficial. Symptomatic treatment: Diuretics are used to relieve fluid congestion and improve symptoms like shortness of breath and swelling. Risk factor management: Controlling high blood pressure is particularly important because hypertension contributes significantly to HFpEF development and progression. Unfortunately, many medications that clearly help HFrEF don't provide the same benefit in HFpEF, making this condition more challenging to treat. Alternative Approaches for RAS Inhibitor-Intolerant Patients Some patients cannot tolerate ACE inhibitors, ARBs, or ARNis due to side effects. For these patients, a combination of hydralazine and a long-acting nitrate (such as isosorbide dinitrate) reduces mortality as an alternative vasodilator strategy. This combination is particularly beneficial in Black populations, which is important to recognize as a health equity consideration. Other Medications Digoxin: This older medication was once a cornerstone of heart failure therapy but provides no mortality benefit and is now reserved only for specific situations: patients with refractory symptoms, those with concurrent atrial fibrillation (where it can help control heart rate), or those with chronic low blood pressure who tolerate it poorly. Diuretics: Loop diuretics, thiazide-like diuretics, and potassium-sparing diuretics treat fluid accumulation. However, strong evidence of mortality benefit exists mainly for mineralocorticoid antagonists (the potassium-sparing class). Other diuretics are used primarily for symptom relief rather than disease modification. Anemia treatment: Treating anemia in chronic heart failure improves quality of life, reduces symptom severity (New York Heart Association classification), and lowers mortality. European guidelines recommend screening for iron deficiency and treating with intravenous iron when deficiency is identified. Anticoagulation: Anticoagulation is considered for patients with ejection fraction below 35% who have atrial fibrillation, prior embolic events, or other high-risk thromboembolic conditions. This prevents stroke and systemic embolism in these vulnerable patients. <extrainfo> Ivabradine: This medication selectively slows heart rate by inhibiting the sinoatrial node. It's indicated for symptomatic HFrEF patients who are on maximally tolerated beta-blocker doses, have a normal heart rhythm (not atrial fibrillation), and have a resting heart rate above 70 beats per minute. Ivabradine reduces heart failure-related hospitalizations in this specific population. </extrainfo>